Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer

Published:2013-01 Issue:1 Volume:79 Page:40-45
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Lee Ha Yeon,Ahn Hee Kyung,Jeong Ji Yun,Kwon Mi Jung,Han Jung-Ho,Sun Jong-Mu,Ahn Jin Seok,Park Keunchil,Choi Yoon-La,Ahn Myung-Ju

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

4. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers;Targeted Oncology;2023-11

2. Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery;Journal of Korean Neurosurgical Society;2021-03-01

3. Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC;Therapeutic Strategies to Overcome ALK Resistance in Cancer;2021

4. Mechanisms of resistance to pemetrexed in non-small cell lung cancer;Translational Lung Cancer Research;2019-12

5. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement;Cells;2019-11-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3